Michael Gibbons
Trinity College Dublin(IE)University of Exeter(GB)Royal Devon & Exeter NHS Foundation Trust(GB)Royal Devon & Exeter NHS Foundation Trust(GB)Royal Devon and Exeter Hospital(GB)Benchmark Research (United States)(US)Heavitree Hospital(GB)NIHR Exeter Clinical Research Facility(GB)Peninsula College of Medicine and Dentistry(GB)
Publications by Year
Research Areas
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease (COPD) Research, Systemic Sclerosis and Related Diseases, Long-Term Effects of COVID-19, Sarcoidosis and Beryllium Toxicity Research
Most-Cited Works
- → Regulation of Transforming Growth Factor-β1–driven Lung Fibrosis by Galectin-3(2011)513 cited
- → Ly6Chi Monocytes Direct Alternatively Activated Profibrotic Macrophage Regulation of Lung Fibrosis(2011)466 cited
- → Respiratory follow-up of patients with COVID-19 pneumonia(2020)395 cited
- → Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial(2018)259 cited
- → Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial(2022)248 cited
- → Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study(2020)237 cited